• 14 patents granted, including 8 in the US and 6 in Europe
• Field trials expanded across new crops, including rice, and new territories
• Latest field trials show efficacy of bioinsecticides at least 85% compared to commercial alternatives

SOLASTA® Bio, a leading agri-biotech company specialising in the next generation of green insecticides, has announced significant progress in expanding its intellectual property portfolio alongside strong field trial results that demonstrate the broad applicability of its technology platform as a viable crop protection solution.

The company now holds a total of 14 granted patents for its peptides, including eight in the United States and six in Europe. These newly granted patents strengthen SOLASTA® Bio global protection strategy and support the commercial rollout of its sustainable crop protection products.

The expanding portfolio reflects the company's ongoing progress towards regulatory readiness and long-term value creation for growers and partners worldwide. SOLASTA® Bio continues to advance a pipeline of nature-inspired bioinsecticides designed to deliver high efficacy, insect pest selectivity, and environmentally responsible performance.

Building on over 50 greenhouse and field trials to date, SOLASTA® Bio has expanded its trials programme to include rice and continued testing on leafy greens and high-value soft fruit crops, demonstrating the versatility of its peptide-based platform across diverse crops and geographies.

Recent trials in Thailand targeting rice have shown promising results against plant hoppers, while trials on berries including strawberries in the US, UK and Italy continue to show strong efficacy against Spotted Wing Drosophila. The company has also extended trials to Lepidoptera and aphids on leafy vegetables across multiple territories, addressing key pest challenges in these important crops.

Across almost all trials to date, SOLASTA® Bio's peptide candidates have consistently shown high efficacy at or above 85% compared to commercial standards, with many treatments achieving efficacy levels above 85%. Critically, no phytotoxicity has been observed in any field trial, and no negative impact on beneficial insects has been recorded.

Shireen Davies, CEO and co-founder of SOLASTA® Bio said: "These patent grants represent a paradigm shift in crop protection, demonstrating that nature-inspired peptides can be effectively protected for commercial deployment. For potential partners and customers, this provides crucial confidence that our technology is not only highly effective but also commercially secure.

"Combined with our expanding field trials programme, these developments position SOLASTA Bio exceptionally well as we advance toward commercialisation. The breadth of our trials, from rice in Asia to soft fruit in Europe and the US, demonstrates the global applicability of our platform and our ability to address pest challenges across diverse crops and geographies."

SOLASTA Bio's technology is based on insect 'neuropeptides', which control essential physiological functions. By disrupting these functions in target pests such as aphids, whitefly, lepidoptera and plant hoppers, the bioinsecticides eliminate pest species while remaining safe for the environment and beneficial pollinators such as bees.

The company has recently strengthened its US operations with the appointment of a new Field Trials Manager, supporting the expansion of trials activity in North America.

These latest achievements build on SOLASTA Bio's strong momentum following an oversubscribed $14 million Series A funding round in September 2024. The round attracted leading agricultural and life science investors, including Forbion BioEconomy Fund, FMC Ventures and Corteva Catalyst, underscoring industry confidence in the company's technology.